In the following video, Fool contributor Maxxwell Chatsko analyzes Amgen's (NASDAQ:AMGN) novel approach to treating late-stage melanoma. The biotechnology giant announced positive top-line results in March with detailed overall survival data on its way in late 2013. While the overall market for melanoma is large, patients with late stage melanoma have substantially fewer treatment options.
Investors are poised to capitalize on the Amgen's focus on biologics, which has already begun paying off so far in 2013. For the most part, Wall Street left this drug's potential out of the company's valuation and had to move quickly to adjust for the surprising preliminary results announced during the first quarter. Can this first-of-its-kind cancer immunotherapy revolutionize the cancer market at large and lead to even more gains?
Fool contributor Maxx Chatsko and Erin Miller have no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.